NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer
Generation Bio Co. - Common stock (GBIO)
Company Research
Source: GlobeNewswire
Dr. McDonough brings global company-building, commercial strategy, and R&D leadership experience to the Company ahead of key clinical milestones NodThera plans to report results from two Phase 2 cardiometabolic trials RESOLVE-1 and RESOLVE-2 in mid-2026 and third quarter 2026 respectively Company preparing to begin cardiometabolic Phase 3 trial in 1H 2027 BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address unmet needs in cardiometabolic and neuroinflammatory diseases driven by the NLRP3/IL-6/IL-1 inflammation pathway, announced the appointment of Geoff McDonough, M.D., as Chief Executive Officer. Dr. McDonough is a seasoned physician-executive with extensive global biopharma industry experience who joins NodThera’s management team ahead of a series of significant anticipated clinical milestones. “The NLRP3/IL-6/IL-1 pathway underlies sev
Show less
Read more
Impact Snapshot
Event Time:
GBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GBIO alerts
High impacting Generation Bio Co. - Common stock news events
Weekly update
A roundup of the hottest topics
GBIO
News
- Generation Bio (NASDAQ:GBIO) was upgraded by analysts at Zacks Research to a "hold" rating.MarketBeat
- XOMA Royalty announces CFO transition [Seeking Alpha]Seeking Alpha
- Generation Bio (NASDAQ:GBIO) had its "market perform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- ‘Zombie' biotech buyer Xoma to acquire Generation Bio [Yahoo! Finance]Yahoo! Finance
- Generation Bio (NASDAQ:GBIO) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $5.50 price target on the stock, down previously from $7.00.MarketBeat
GBIO
Earnings
- 11/5/25 - Beat
GBIO
Sec Filings
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- GBIO's page on the SEC website